Cooper Companies stock presents a clear valuation debate right now. The Discounted Cash Flow (DCF) intrinsic value estimate points to a large gap to the current share price, while traditional market multiples suggest the stock already trades at a premium, and the broader valuation checks lean cautious.

• Over the past 5 years, Cooper Companies has delivered a share price decline of 32.3%, which raises the question of whether the current price fairly reflects the company’s long term cash flow potential.
• Future cash generation from recurring medical products and services can support the intrinsic value case, although any pressure on margins or higher capital spending may limit how much of that value reaches shareholders.
• On Simply Wall St’s broader valuation checks, Cooper Companies only scores 2 out of 6, which points to a stock that does not screen as a straightforward bargain on most measures.

The issue now is whether investors should rely more on the DCF style intrinsic value signal or place greater weight on the richer earnings multiples and low value score, which may indicate that Cooper Companies is already pricing in much of its quality.

Does Cooper Companies Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) method looks at the cash Cooper Companies may generate for shareholders over time. In this model, the latest twelve month free cash flow is about $525.3 million, with projections that assume growing free cash flows rather than a shrinking business. Those cash flows are discounted back to today using a 2 Stage Free Cash Flow to Equity approach, which aims to capture an earlier growth phase and a later steady phase.

Based on these inputs, the DCF model arrives at an intrinsic value of about $148 per share. Relative to the current share price, the calculation implies the stock is 48.9% undervalued. In this framework, the market price is below the value suggested by this cash flow profile.

On this cash flow view, Cooper Companies stock currently screens as undervalued.

Our Discounted Cash Flow (DCF) analysis suggests Cooper Companies is undervalued by 48.9%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Does Cooper Companies Look Pricey on Earnings?

P/E is a useful lens for Cooper Companies because earnings remain a key anchor for how the market prices established medical equipment businesses. Cooper Companies currently trades on a P/E of about 62.7x, which is well above the Medical Equipment industry average of 27.2x and the peer average near 24.9x. That is a sizeable premium for a stock in this sector.

The tailored fair P/E ratio for Cooper Companies is estimated at around 36.2x, based on factors such as its industry, scale, profitability profile and risk. The current 62.7x multiple sits far above this level, which means investors are paying much more per dollar of earnings than the model suggests would be typical for a company with these characteristics.

On the P/E measure, Cooper Companies stock currently screens as overvalued compared with both its fair multiple and its industry benchmarks.

The Cooper Companies Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Cooper Companies are designed to bridge this valuation puzzle by spelling out what would need to be true about Cooper Companies' future growth, margins and earnings for the stock to be worth materially more or less than today's price. They are available on the company's Community page. Each one frames fair value as a thesis about the business that can be tracked over time rather than a one off snapshot.

Community views on Cooper Companies are sharply split, with one narrative focused on product driven upside and the other on a ceiling from execution and margin risks.

Bull case: 6% undervalued

"The company recently resolved its manufacturing constraints for MyDAY, its premium daily silicone hydrogel contact lens, and is now accelerating global rollout with expanded fitting sets, trial lenses, and over 30 new private label contracts..."

Bear case: 12% overvalued

"Although demand for daily silicone hydrogel lenses and premium products like MyDay multifocal and Energys is currently supporting solid contact lens revenue, the ongoing transition away from older hydrogel products in Japan and other parts of Asia Pac could weigh on the overall CooperVision revenue mix..."

Do you think there's more to the story for Cooper Companies? Head over to our Community to see what others are saying!

The Bottom Line

Cooper Companies presents a split picture. The Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside, while the rich P/E multiple suggests the stock already prices in strong expectations. The low broader value score reinforces that most checks do not flag Cooper Companies as an obvious bargain despite that DCF signal. The key question from here is whether the company can sustain cash generation and margins enough to justify both the premium multiple and the intrinsic value case, or whether the current discount will ultimately prove to be a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.